IT1306704B1 - Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. - Google Patents

Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.

Info

Publication number
IT1306704B1
IT1306704B1 IT1999RM000333A ITRM990333A IT1306704B1 IT 1306704 B1 IT1306704 B1 IT 1306704B1 IT 1999RM000333 A IT1999RM000333 A IT 1999RM000333A IT RM990333 A ITRM990333 A IT RM990333A IT 1306704 B1 IT1306704 B1 IT 1306704B1
Authority
IT
Italy
Prior art keywords
ngf
act
synthetic
monoclonal antibodies
antagonist molecules
Prior art date
Application number
IT1999RM000333A
Other languages
English (en)
Inventor
Michal Novak
Original Assignee
Sirs Societa Italiana Per La R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11406787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1306704(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sirs Societa Italiana Per La R filed Critical Sirs Societa Italiana Per La R
Priority to IT1999RM000333A priority Critical patent/IT1306704B1/it
Publication of ITRM990333A0 publication Critical patent/ITRM990333A0/it
Priority to AU51019/00A priority patent/AU776457B2/en
Priority to JP2001500668A priority patent/JP4917226B2/ja
Priority to CA2373274A priority patent/CA2373274C/en
Priority to PCT/IT2000/000218 priority patent/WO2000073344A2/en
Priority to DK00935482.0T priority patent/DK1181318T4/da
Priority to EP00935482A priority patent/EP1181318B2/en
Priority to US09/979,710 priority patent/US7601352B1/en
Priority to AT00935482T priority patent/ATE263188T1/de
Priority to PT00935482T priority patent/PT1181318E/pt
Priority to ES00935482T priority patent/ES2218163T5/es
Priority to DE60009484T priority patent/DE60009484T3/de
Publication of ITRM990333A1 publication Critical patent/ITRM990333A1/it
Publication of IT1306704B1 publication Critical patent/IT1306704B1/it
Application granted granted Critical
Priority to US12/557,825 priority patent/US8486401B2/en
Priority to JP2011180419A priority patent/JP2012040007A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT1999RM000333A 1999-05-26 1999-05-26 Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. IT1306704B1 (it)

Priority Applications (14)

Application Number Priority Date Filing Date Title
IT1999RM000333A IT1306704B1 (it) 1999-05-26 1999-05-26 Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DE60009484T DE60009484T3 (de) 1999-05-26 2000-05-26 Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate
US09/979,710 US7601352B1 (en) 1999-05-26 2000-05-26 Monoclonal antibodies and antigen binding fragments thereof capable of binding TrkA and inhibiting the functional activation of TrkA
AT00935482T ATE263188T1 (de) 1999-05-26 2000-05-26 Als ngf-antagonisten wirkende monoklonale antiköper und deren synthetische und biotechnologische derivate
CA2373274A CA2373274C (en) 1999-05-26 2000-05-26 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
PCT/IT2000/000218 WO2000073344A2 (en) 1999-05-26 2000-05-26 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
DK00935482.0T DK1181318T4 (da) 1999-05-26 2000-05-26 Monoklonale antistoffer samt syntetiske og bioteknologiske derivater deraf, der virker som NGF-antagonistmolekyler
EP00935482A EP1181318B2 (en) 1999-05-26 2000-05-26 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as ngf-antagonist molecules
AU51019/00A AU776457B2 (en) 1999-05-26 2000-05-26 Monoclonal antibodies, synthetic and biotechnological derivatives thereof acting as NGF-antagonist molecules
JP2001500668A JP4917226B2 (ja) 1999-05-26 2000-05-26 Ｎｇｆ−アンタゴニスト分子として作用するモノクローナル抗体、その合成及び生命工学的誘導体
PT00935482T PT1181318E (pt) 1999-05-26 2000-05-26 Anticorpos monoclonais seus derivados sinteticos e biotecnologicos actuando como moleculas antagonistas de nge
ES00935482T ES2218163T5 (es) 1999-05-26 2000-05-26 Anticuerpos monoclonales y sus derivados sintéticos y biotecnológicos que actúan como moléculas antagonistas de NGF
US12/557,825 US8486401B2 (en) 1999-05-26 2009-09-11 Monoclonal antibodies binding to TrkA and acting as NGF-antagonist molecules and their use for treating pain induced by NGF
JP2011180419A JP2012040007A (ja) 1999-05-26 2011-08-22 Ｎｇｆ−アンタゴニスト分子として作用するモノクローナル抗体、その合成及び生命工学的誘導体

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1999RM000333A IT1306704B1 (it) 1999-05-26 1999-05-26 Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.

Publications (3)

Publication Number Publication Date
ITRM990333A0 ITRM990333A0 (it) 1999-05-26
ITRM990333A1 ITRM990333A1 (it) 2000-11-26
IT1306704B1 true IT1306704B1 (it) 2001-10-02

Family

ID=11406787

Family Applications (1)

Application Number Title Priority Date Filing Date
IT1999RM000333A IT1306704B1 (it) 1999-05-26 1999-05-26 Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.

Country Status (12)

Country Link
US (2) US7601352B1 (it)
EP (1) EP1181318B2 (it)
JP (2) JP4917226B2 (it)
AT (1) ATE263188T1 (it)
AU (1) AU776457B2 (it)
CA (1) CA2373274C (it)
DE (1) DE60009484T3 (it)
DK (1) DK1181318T4 (it)
ES (1) ES2218163T5 (it)
IT (1) IT1306704B1 (it)
PT (1) PT1181318E (it)
WO (1) WO2000073344A2 (it)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
KR20100132559A (ko) * 2001-05-30 2010-12-17 제넨테크, 인크. 다양한 질환의 치료에 유용한 항-엔지에프 항체
US20040009549A1 (en) * 2001-12-31 2004-01-15 Sugen, Inc. Method for detecting remote homologues and novel kinases identified with the method
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US7255860B2 (en) 2002-10-08 2007-08-14 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody
WO2004032870A2 (en) 2002-10-08 2004-04-22 Rinat Neuroscience Corp. Methods for treating post-surgical pain by admisnistering a nerve growth factor antagonist and compositions containing the same
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
DK1575517T3 (da) 2002-12-24 2012-05-14 Rinat Neuroscience Corp Anti-ngf-antistoffer og fremgangsmåder til anvendelse af samme
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
JP5096167B2 (ja) 2005-01-24 2012-12-12 メドイミューン リミテッド Ｎｇｆに対する特異的結合メンバー
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
CA2608009A1 (en) 2005-05-16 2006-11-23 Astrazeneca Ab Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
ITRM20050290A1 (it) * 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) * 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
BRPI0618011A2 (pt) 2005-10-28 2011-08-16 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, métodos para produzir um efeito anti-proliferativo e um efeito pró-apoptósico em um animal de sangue quente, para tratar doença e para produzir um efeito inibidor de jak em um animal de sangue quente
TW200826937A (en) * 2006-11-01 2008-07-01 Astrazeneca Ab New use
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
PL2187964T3 (pl) 2007-08-10 2015-03-31 Regeneron Pharma Ludzkie przeciwciała o wysokim powinowactwie przeciw ludzkiemu czynnikowi wzrostu nerwu
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
BRPI0905955A8 (pt) * 2008-02-04 2018-05-08 Lay Line Genomics Spa anticorpo ani trka, anticorpo ou derivado, derivado de um anticorpo, combinação de um anticorpo ou derivado, composição farmaceutica, método, polipetídeo, ácido nucléico codificante de um aniticorpo ou derivado do mesmo, vetor, sistema de expressão ,mamífero transgênico não humano e kit compreendo um anticorpo ou derivado
RU2016116516A (ru) 2008-12-08 2018-12-07 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
ES2514319T3 (es) 2009-05-04 2014-10-28 Abbvie Research B.V. Anticuerpos contra el factor de crecimiento nervioso (NGF) con estabilidad in vivo mejorada
ES2665954T3 (es) 2010-08-19 2018-04-30 Zoetis Belgium S.A. Anticuerpos anti-NGF y su uso
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9102673B2 (en) 2011-07-12 2015-08-11 Merck Sharp & Dohme Corp. Substituted pyrrolo[3,2-c]pyridines as TrkA kinase inhibitors
WO2013176970A1 (en) 2012-05-22 2013-11-28 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
UA113879C2 (xx) 2012-06-08 2017-03-27 ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ
EP2674439B1 (en) * 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
CN109820853B (zh) 2014-02-05 2022-05-10 Vm肿瘤药物有限责任公司 取代的杂环化合物在制备治疗癌症药物中的用途
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
AR114110A1 (es) * 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
BR112020017701A2 (pt) 2018-03-12 2020-12-29 Zoetis Services Llc Anticorpos anti-ngf e métodos dos mesmos
TW202210467A (zh) 2020-05-28 2022-03-16 美商美國禮來大藥廠 TrkA抑制劑
WO2023125490A1 (en) * 2021-12-28 2023-07-06 4B Technologies (Suzhou) Limited TrkA ANTIBODY AND APPLICATION THEREOF
EP4514998A1 (en) 2022-04-27 2025-03-05 Regeneron Pharmaceuticals, Inc. Treatment of arthropathy based upon stratification of osteoarthritis polygenic risk score
CN120752534A (zh) 2023-03-17 2025-10-03 瑞泽恩制药公司 骨关节炎(oa)的蛋白质组学风险评分
WO2026054762A1 (en) 2024-09-05 2026-03-12 Regeneron Pharmaceuticals, Inc. Proteomic risk score for adjudicated arthropathy (aa)
WO2026111937A2 (en) 2024-11-25 2026-05-28 Eli Lilly And Company Trka rna interference agents and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3418389A (en) * 1988-03-28 1989-10-16 Regents Of The University Of California, The Nerve growth factor peptides
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0471205A1 (en) 1990-08-15 1992-02-19 E.R. SQUIBB & SONS, INC. Monoclonal antibodies which bind TRK proto-oncogene protein
WO1993011794A1 (en) * 1991-12-13 1993-06-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5830470A (en) * 1992-09-07 1998-11-03 Kyowa Hakko Kogyo Co., Ltd. Humanized antibodies to ganglioside GM2
KR100335584B1 (ko) * 1992-10-28 2002-11-29 제넨테크, 인코포레이티드 혈관내피세포성장인자에대한길항제
US5753225A (en) 1993-12-03 1998-05-19 The Regents Of The University Of California Antibodies that mimic actions of neurotrophins
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
ES2233974T3 (es) * 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
GB9525180D0 (en) 1995-12-08 1996-02-07 Univ Mcgill Design of hormone-like antibodies with agonistic and antagonistic fuctions
US20020064528A1 (en) * 2000-01-28 2002-05-30 Zhenping Zhu Antibodies specific to KDR and uses thereof
IT1306704B1 (it) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
FR2807660A1 (fr) 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
BRPI0905955A8 (pt) 2008-02-04 2018-05-08 Lay Line Genomics Spa anticorpo ani trka, anticorpo ou derivado, derivado de um anticorpo, combinação de um anticorpo ou derivado, composição farmaceutica, método, polipetídeo, ácido nucléico codificante de um aniticorpo ou derivado do mesmo, vetor, sistema de expressão ,mamífero transgênico não humano e kit compreendo um anticorpo ou derivado

Also Published As

Publication number Publication date
JP2012040007A (ja) 2012-03-01
PT1181318E (pt) 2004-08-31
JP4917226B2 (ja) 2012-04-18
CA2373274A1 (en) 2000-12-07
ATE263188T1 (de) 2004-04-15
EP1181318A2 (en) 2002-02-27
AU5101900A (en) 2000-12-18
US8486401B2 (en) 2013-07-16
ITRM990333A0 (it) 1999-05-26
WO2000073344A2 (en) 2000-12-07
CA2373274C (en) 2012-08-14
WO2000073344A3 (en) 2001-06-28
ES2218163T3 (es) 2004-11-16
US7601352B1 (en) 2009-10-13
JP2003502029A (ja) 2003-01-21
ITRM990333A1 (it) 2000-11-26
ES2218163T5 (es) 2012-06-06
DK1181318T3 (da) 2004-07-12
DE60009484T2 (de) 2005-03-24
US20110206682A1 (en) 2011-08-25
DK1181318T4 (da) 2012-05-29
EP1181318B1 (en) 2004-03-31
DE60009484D1 (de) 2004-05-06
EP1181318B2 (en) 2012-03-28
WO2000073344A9 (en) 2002-03-07
AU776457B2 (en) 2004-09-09
DE60009484T3 (de) 2012-06-14

Similar Documents

Publication Publication Date Title
DK1181318T4 (da) Monoklonale antistoffer samt syntetiske og bioteknologiske derivater deraf, der virker som NGF-antagonistmolekyler
DK1287130T3 (da) Cytokinreceptorunderenhedproteiner fra pattedyr, tilhörende reagenser og fremgangsmåder
BRPI0416211A (pt) il-23 e seu receptor; reagentes relacionados e métodos
DE60025832D1 (de) Mehrere zytokin-antikörper komplexen
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
BR0113921A (pt) ácidos nucléicos e polipeptìdeos receptores
BR0315123A (pt) Composições farmacêuticas direcionadas a receptores erb-b1
ATE469913T1 (de) Antagonisten des nogo-rezeptors
WO2001090358A3 (en) Mammalian receptor proteins; related reagents and methods
EP1433792A3 (en) Human receptor proteins, related reagents and methods
EP2292760A3 (en) Mammalian cytokines, receptors, related reagents and methods
PT759942E (pt) Receptor de interleucina-15
WO2001036467A3 (en) Mammalian receptor proteins; related reagents and methods
WO1999046379A3 (en) Human receptor proteins; related reagents and methods
DE69938725D1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
NZ515382A (en) OX2 receptor homologs
WO2005065711A3 (en) Mammalian receptor proteins; related reagents and methods
WO1999019480A3 (en) Human receptor proteins; related reagents and methods
CY1114280T1 (el) Αντισωματα ανταγωνιστων των κυτοκινων θηλαστικων ή οι υποδοχεις τους για την αγωγη της αλλεργιας